Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Dividends payables (2022)

Gyre Therapeutics has reported Dividends payables over the past 1 years, most recently at $7.6 million for Q4 2022.

Quarterly Dividends payables changed N/A to $7.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2022, changed N/A year-over-year, with the annual reading at $7.6 million for FY2022, N/A changed from the prior year.
Dividends payables was $7.6 million for Q4 2022 at Gyre Therapeutics.
Over five years, Dividends payables peaked at $7.6 million in Q4 2022 and troughed at $7.6 million in Q4 2022.